SPOTLIGHT: Analysts ponder Cervarix delay

There's been a considerable number of post mortems on the FDA's decision to delay a decision on GlaxoSmithKlines's Cervarix, a cervical cancer vaccine that is already approved in Europe and has the capacity to become a blockbuster therapy in competition with Merck's Gardasil. Motley Fool's Brian Lawler is betting that the European Medicine Agency's green light indicates only a small hold-up for Cervarix. Glaxo added considerably to the uncertainty around the delay when it declined to spell out exactly what the regulators want to know. In the meantime, though, Gardasil has gained even more time to establish itself as the leader in the HPV vaccine race. Article

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.